Neurovascular embolization devices market seen reaching $1.91 billion by 2030

The Business Research Company projects steady growth in the global neurovascular embolization devices market, driven by rising hemorrhage cases, broader use of neurointerventional procedures and stronger demand for minimally invasive stroke care. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Neurovascular embolization devices are used to treat brain and central nervous system vessel abnormalities that can lead to bleeding, stroke and other serious complications. - The market is expanding as hospitals, clinicians and patients increasingly favor less invasive neurovascular procedures. - Rising hemorrhage rates are a direct demand driver for devices used to block abnormal blood vessels and reduce brain damage.

What happened: - The Business Research Company published a 2026 market report on the neurovascular embolization devices market with a forecast through 2035. - The market is projected to rise from $1.38 billion in 2025 to $1.47 billion in 2026. - The report estimates the market will reach $1.91 billion by 2030. - The company places the market at a 6.2% CAGR from 2025 to 2026 and a 6.8% CAGR through 2030. - The release was dated Aug. 19, 2026, from London. - The company offered a free sample of the report and a full market report.

The details: - The report links near-term growth to more cerebral aneurysm cases, wider adoption of neurointerventional procedures, more specialized neurovascular professionals, higher hospital investment in neurocare infrastructure and stronger demand for minimally invasive stroke treatment. - Longer-term growth is tied to demand for advanced stroke management technologies, higher R&D spending in neurovascular care, an aging population prone to vascular disorders, broader acceptance of embolization devices and a push for better clinical outcomes. - Key trends identified in the report include more frequent use of flow diversion stents, greater adoption of liquid embolic agents, improved coil coatings and more precision-targeted devices. - Neurovascular embolization devices are described as tools that block or divert blood flow in conditions such as cerebral aneurysms, arteriovenous malformations and arteriovenous fistulas. - Hemorrhage prevalence is a major growth driver, with higher rates tied to aging populations, hypertension and wider anticoagulant use. - Research from King’s College London in February 2024 projects cases and deaths related to intracerebral hemorrhage among people aged 70 to 95 in the UK will rise 59.4% by 2050. - In 2025, North America held the largest share of the global market because of advanced healthcare infrastructure and strong clinical expertise. - Asia-Pacific is expected to be the fastest-growing region over the forecast period because of higher healthcare spending, larger patient pools and rising awareness of neurovascular disorders. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 reports include market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspot infographics and updated technology and trend analysis.

Between the lines: - The forecast points to a market moving from broad clinical need to more specialized, device-driven therapy. - Regional growth suggests future competition may shift toward Asia-Pacific even as North America remains the largest installed market. - The report’s emphasis on coatings, stents and liquid embolics signals a category where product differentiation may depend on procedural precision and outcome improvement.

What's next: - The market is expected to keep growing as stroke care, hemorrhage treatment and neurointerventional adoption expand through 2030. - Hospitals and device makers are likely to focus on advanced embolization technologies that support minimally invasive treatment and better clinical results. - The Business Research Company says its expanded 2026 research tools are designed to help buyers assess market opportunity and competitive positioning.